Claret Asset Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.5M | Sell |
156,526
-821
| -0.5% | -$35.3K | 0.81% | 32 |
|
|
2026
Q1 | $5.78M | Buy |
157,347
+4,737
| +3% | +$224K | 0.69% | 36 |
|
|
2025
Q4 | $7.76M | Buy |
152,610
+7,612
| +5% | +$389K | 0.9% | 29 |
|
|
2025
Q3 | $8.05M | Buy |
144,998
+114,568
| +376% | +$6.71M | 0.96% | 27 |
|
|
2025
Q2 | $2.1M | Buy |
30,430
+101
| +0.3% | +$6.87K | 0.27% | 55 |
|
|
2025
Q1 | $2.11M | Buy |
30,329
+117
| +0.4% | +$9.66K | 0.3% | 49 |
|
|
2024
Q4 | $2.6M | Buy |
30,212
+22,921
| +314% | +$2.48M | 0.41% | 47 |
|
|
2024
Q3 | $868K | Hold |
7,291
| – | – | 0.14% | 74 |
|
|
2024
Q2 | $1.04M | Sell |
7,291
-675
| -8% | -$89.4K | 0.19% | 64 |
|
|
2024
Q1 | $1.02M | Buy |
7,966
+650
| +9% | +$77.4K | 0.17% | 67 |
|
|
2023
Q4 | $757K | Hold |
7,316
| – | – | 0.14% | 79 |
|
|
2023
Q3 | $665K | Buy |
7,316
+66
| +0.9% | +$5.81K | 0.13% | 77 |
|
|
2023
Q2 | $587K | Hold |
7,250
| – | – | 0.11% | 85 |
|
|
2023
Q1 | $577K | Hold |
7,250
| – | – | 0.11% | 89 |
|
|
2022
Q4 | $491K | Hold |
7,250
| – | – | 0.11% | 92 |
|
|
2022
Q3 | $361K | Hold |
7,250
| – | – | 0.09% | 98 |
|
|
2022
Q2 | $404K | Hold |
7,250
| – | – | 0.09% | 101 |
|
|
2022
Q1 | $403K | Hold |
7,250
| – | – | 0.08% | 103 |
|
|
2021
Q4 | $406K | Sell |
7,250
-72
| -1% | -$3.9K | 0.08% | 112 |
|
|
2021
Q3 | $351K | Hold |
7,322
| – | – | 0.06% | 124 |
|
|
2021
Q2 | $307K | Hold |
7,322
| – | – | 0.05% | 141 |
|
|
2021
Q1 | $247K | Hold |
7,322
| – | – | 0.05% | 151 |
|
|
2020
Q4 | $256K | Sell |
7,322
-616
| -8% | -$21.3K | 0.05% | 148 |
|
|
2020
Q3 | $276K | Hold |
7,938
| – | – | 0.06% | 136 |
|
|
2020
Q2 | $260K | Sell |
7,938
-7,980
| -50% | -$255K | 0.06% | 138 |
|
|
2020
Q1 | $479K | Sell |
15,918
-3,410
| -18% | -$102K | 0.14% | 88 |
|
|
2019
Q4 | $559K | Sell |
19,328
-138
| -0.7% | -$3.82K | 0.11% | 103 |
|
|
2019
Q3 | $503K | Sell |
19,466
-94
| -0.5% | -$2.38K | 0.1% | 104 |
|
|
2019
Q2 | $499K | Hold |
19,560
| – | – | 0.1% | 107 |
|
|
2019
Q1 | $512K | Buy |
19,560
+94
| +0.5% | +$2.31K | 0.1% | 106 |
|
|
2018
Q4 | $448K | Hold |
19,466
| – | – | 0.1% | 109 |
|
|
2018
Q3 | $459K | Buy |
19,466
+1,808
| +10% | +$44.1K | 0.09% | 114 |
|
|
2018
Q2 | $407K | Buy |
17,658
+9,000
| +104% | +$214K | 0.08% | 118 |
|
|
2018
Q1 | $213K | Hold |
8,658
| – | – | 0.05% | 144 |
|
|
2017
Q4 | $232K | Buy |
+8,658
| New | +$220K | 0.05% | 140 |
|
Other funds holding NVO
F
Claret Asset Management's NVO Position: Q2 2026 in Review
Claret Asset Management reduced its Novo Nordisk (NVO) stake by 0.52% in Q2 2026, selling an estimated $35.3K and leaving 156,526 shares worth $7.5M. The position accounts for 0.81% of the portfolio, ranked #32.
Claret Asset Management first reported a position in NVO in Q4 2017 and has held it in 35 quarters since. The position peaked at $8.05M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Claret Asset Management held 156,526 shares of Novo Nordisk worth $7.5M as of Q2 2026.
- Claret Asset Management sold 821 Novo Nordisk shares in Q2 2026, an estimated $35.3K.
- Novo Nordisk made up 0.81% of Claret Asset Management's portfolio in Q2 2026, its #32 holding.
- Claret Asset Management first reported a position in Novo Nordisk in Q4 2017 and has held it in 35 quarters since.
- Claret Asset Management's Novo Nordisk position peaked at $8.05M in Q3 2025.
- 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.